SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Traders are flooding NVDA ahead of its earnings, with sentiment split between those expecting a massive post-earnings rally and those bracing for a sell-the-news drop despite an expected beat. Discussions also highlight concerns over circular financing and Burry's disclosed shorts.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as traders pile in after its H1 earnings showed explosive revenue growth and raised guidance, with bullish chatter about a potential short squeeze colliding with bearish concerns over widening losses and margin pressure.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

ANF is surging after a blowout quarter and sharply raised full-year guidance, with chatter focused on a massive short squeeze as traders debate whether momentum stays or fades. The conversation is split between bullish buyback and tariff-refund catalysts versus bearish calls that the spike is a trap.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is surging on its $795M licensing deal with SK Biopharmaceuticals for the epilepsy drug opakalim, which provides non-dilutive cash and de-risks upcoming catalysts. Retail traders are hyped over the extended cash runway and now focus on the pivotal obesity data readout expected in late 2026, seeing the deal as validation of the pipeline.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum shares are under pressure after CFO John Markovich announced his retirement, triggering a sharp selloff amid concerns about leadership stability and the company's valuation. The community is split between those seeing a buying opportunity on the dip and those citing weak fundamentals, while broader quantum sector weakness amplifies the decline.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RVMD is spiking on FDA approval of daraxonrasib for pancreatic cancer, with the community highlighting data that nearly doubled overall survival and slashed death risk by 60%. The buzz is centered on how this validates the drug's blockbuster potential and fuels speculation about a high-premium buyout from big pharma, while also sparking comparisons to other cancer-focused names like SLS.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO is trending due to a highly polarized social media debate centered on its nuclear/AI catalyst narrative, including the Groves reactor criticality and major partnership agreements, versus persistent bearish arguments about zero revenue, insider selling, and valuation. This tug-of-war is driving extreme volatility, with bulls pointing to execution milestones and long-term AI power demand, while bears highlight the lack of current financials and short-term price drops.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is getting hammered as Meta's massive youth-addiction settlement shines a spotlight on the legal overhang facing all social media stocks, with a Ninth Circuit ruling denying Section 230 immunity allowing 3,000+ addiction lawsuits to proceed against SNAP, compounded by CTO Robert Murphy's $21.6M insider sale. The community is split between treating this as a stop-loss raid and buying opportunity ahead of the Sept. 16 SPECS launch versus a genuine repricing of litigation exposure.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal is trending on strong Q2 momentum and persistent buyout/M&A speculation, with traders debating whether aggressive spending is a red flag or justified reinvestment in its MASH lead. The community remains split between calling recent volatility an overreaction and worrying about near-term expenses, while broader GLP-1 competition and pipeline expansion keep the story active.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Investors are closely monitoring upcoming clinical catalysts and regulatory milestones for ivonescimab, bolstered by significant insider accumulation and ongoing discussions surrounding its competitive positioning in oncology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MBC - MasterBrand Inc - 10K - Updated Risk Factors 
 
MBC sharpened its risk focus around “financial performance,” added fresh exposure from AI use, deeper supply chain, labor, data security, international trade and manufacturing vulnerabilities, detailed goodwill impairment and leverage tied to its pending American Woodmark merger, and flagged new deal-failure and anti-takeover/shareholder litigation constraints. #HomeImprovement #ArtificialIntelligence #SupplyChainRisk #FinancialPerformance #MergersAndAcquisitions 
 
🟢 Added 🟠 Removed 
 
https://d-risk.ai/MBC/10-K/2026-02-13

D-risk

dRISK

StockTwits Web

MasterBrand Inc

 - MasterBrand Inc - 10K - Updated Risk Factors 
 
MBC sharpened its risk focus around “financial performance,” added fresh exposure from AI use, deeper supply chain, labor, data security, international trade and manufacturing vulnerabilities, detailed goodwill impairment and leverage tied to its pending American Woodmark merger, and flagged new deal-failure and anti-takeover/shareholder litigation constraints. 